Search - tctmd.com

Displaying 721 - 740 of 832

Sort: Relevancy | Date

Presentation TCT 2016

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Presenter: William A. Gray, Stephan Windecker

October 31, 2016

Presentation TCT 2016

Complications of Structural Heart Disease Intervention

Presenter: George S. Hanzel, Mauricio G. Cohen

October 31, 2016

Presentation TCT 2016

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Presenter: William A. Gray, Stephan Windecker, Vinod H. Thourani

October 31, 2016

Presentation TCT 2016

Congenital Heart Disease: PFO, ASD, PDA and Coarctation

Presenter: Harsimran Sachdeva Singh, John P. Breinholt

October 31, 2016

Presentation TCT 2016

Rationale for and Design of COAPT: What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Michael Argenziano, Alec S. Vahanian, Blase A. Carabello

October 31, 2016

Presentation TCT 2016

Rationale for and Design of TAVR UNLOAD: What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Michael Argenziano, Alec S. Vahanian, Daniel Burkhoff

October 31, 2016

Presentation TCT 2016

TCT 42: Transcatheter Echo Guided Mitral Valve Repair With Neochord Implantation for Posterior Leaflet Disease: Results From Neochord Independent International Registry

Presenter: Stephan Baldus, Allan Schwartz, Andrea Colli

October 31, 2016

Presentation TCT 2016

Rationale for and Design of GALILEO

Presenter: Michael Argenziano, Alec S. Vahanian, Paul Sorajja

October 31, 2016

Presentation TCT 2016

Rationale for and Design of SAPIEN LOW RISK and EVOLUTE LOW RISK

Presenter: Michael Argenziano, Alec S. Vahanian, Patrick T. O'Gara

October 31, 2016

Presentation TCT 2016

Valvular Heart Disease III: Mitral Stenosis, Pulmonic Stenosis, and Tricuspid Regurgitation

Presenter: Michael J. Lim, Payam Dehghani

October 31, 2016

Presentation TCT 2016

Valvular Heart Disease II: Mitral Regurgitation - Edge-to-Edge Repair for DMR and FMR

Presenter: Michael J. Lim, Molly Szerlip

October 31, 2016

Presentation TCT 2016

Combined Single-Session Tavi With Edwards Sapien 3 Aortic Valve and Percutaneous Closure of the Left Atrial Appendage in a Elderly Comorbid Patient

Presenter: Maurice Buchbinder, Horst Sievert, Caterina Gandolfo

October 31, 2016

Presentation TCT 2016

Valvular Heart Disease I: Aortic Stenosis - Valvuloplasty and TAVR

Presenter: Dmitriy N. Feldman, Rahul Sakhuja

October 31, 2016

Presentation TCT 2016

Real-time 3D Guidance in Recanalization of Interrupted Aorta

Presenter: Maurice Buchbinder, Horst Sievert, C. Huie Lin

October 31, 2016

Presentation TCT 2016

Severe Bicuspid Aortic Valve Disease

Presenter: Jean-Claude Laborde, Wilson Y. Szeto, Vinayak Bapat

October 31, 2016

Presentation TCT 2016

LAA Closure With Amplatzer Amulet: A Step-by-Step Approach

Presenter: Maurice Buchbinder, Horst Sievert, Apostolos Tzikas

October 31, 2016

Presentation TCT 2016

Severe AS and Chronic Kidney Disease

Presenter: Howard C. Herrmann, Vinod H. Thourani, Molly Szerlip

October 31, 2016

Presentation TCT 2016

Native RVOT Modification and Hybrid Transcatheter Pulmonary Valve Replacement

Presenter: Maurice Buchbinder, Horst Sievert, C. Huie Lin

October 31, 2016

Presentation TCT 2016

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Presenter: A. Pieter Kappetein, Allan Schwartz, Samir R. Kapadia

October 30, 2016

Presentation TCT 2016

Aortic Stenosis + Concomitant Disease II. TAVR in Patients With Acute and Chronic Coronary Syndromes - When and How Much to Treat

Presenter: A. Pieter Kappetein, Allan Schwartz, James B. Hermiller Jr.

October 30, 2016

Advertisement

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Complications of Structural Heart Disease Intervention

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Congenital Heart Disease: PFO, ASD, PDA and Coarctation

Rationale for and Design of COAPT: What I Expect the Findings to Be But What Wont Surprise Me!

Rationale for and Design of TAVR UNLOAD: What I Expect the Findings to Be But What Wont Surprise Me!

TCT 42: Transcatheter Echo Guided Mitral Valve Repair With Neochord Implantation for Posterior Leaflet Disease: Results From Neochord Independent International Registry

Rationale for and Design of GALILEO

Rationale for and Design of SAPIEN LOW RISK and EVOLUTE LOW RISK

Valvular Heart Disease III: Mitral Stenosis, Pulmonic Stenosis, and Tricuspid Regurgitation

Valvular Heart Disease II: Mitral Regurgitation - Edge-to-Edge Repair for DMR and FMR

Combined Single-Session Tavi With Edwards Sapien 3 Aortic Valve and Percutaneous Closure of the Left Atrial Appendage in a Elderly Comorbid Patient

Valvular Heart Disease I: Aortic Stenosis - Valvuloplasty and TAVR

Real-time 3D Guidance in Recanalization of Interrupted Aorta

Severe Bicuspid Aortic Valve Disease

LAA Closure With Amplatzer Amulet: A Step-by-Step Approach

Severe AS and Chronic Kidney Disease

Native RVOT Modification and Hybrid Transcatheter Pulmonary Valve Replacement

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Aortic Stenosis + Concomitant Disease II. TAVR in Patients With Acute and Chronic Coronary Syndromes - When and How Much to Treat

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content